A Phase 2 interventional study of CTP-543 and CTP-543 Matching Placebo in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-04-05.
Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 9th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 2, and was the 4th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:
Sun Pharma Japan Limited · Sites in Japan
Ages 18–65
Sun Pharmaceutical Industries, Inc. · Sites in United States, Canada
Ages 12–17
By country, each count listing its studies:
Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6
First in 2017; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 336 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Concert Pharmaceuticals, one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited: 2 open now, 3 under way, 3 of them phase 3. Of 7 finished, 7 (100%) have results posted.
Among the 10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited, this one is the 9th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 2, and was the 4th registered.
Sun Pharmaceutical Industries Limited’s Alopecia Areata studies by the year they started, since 2017.
1 of the studies testing deuruxolitinib in Alopecia Areata that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sun Pharmaceutical Industries Limited’s 10 in Alopecia Areata:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 x 12 milligrams (mg) CTP-543 tablet and 1 x CTP-543 matching placebo tablet, twice daily (BID) for 24 weeks.
Drug: CTP-543 · Drug: CTP-543 Matching Placebo
Participants received 24 mg (2 x 12 mg) CTP-543 tablets, once daily (QD) and after 12 hours, received 2 x CTP-543 matching placebo tablets, QD for 24 weeks.
Drug: CTP-543 · Drug: CTP-543 Matching Placebo
Administered as 12 mg tablets.
Administered as tablets to aid treatment masking.
Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).
Time frame: Baseline, Week 24
Percentage of Participants Achieving at Least a 90%, 75%, and 50% Reduction in SALT Score From Baseline
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Percentage of participants achieving at least a 50%, 75%, 90% relative reduction in SALT score from baseline at Weeks 4, 8, 12, 16, 20, and 24 are reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Absolute Change From Baseline in SALT Scores at Weeks 4, 8, 12, 16, 20, and 24
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Absolute change equals the difference in SALT measurements (baseline SALT score - follow-up SALT score).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Relative Change From Baseline in SALT Scores at Weeks 4, 8, 12, 16 and 20
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).
Time frame: Baseline, Weeks 4, 8, 12, 16 and 20
Percentage of Participants With Change in Satisfaction of Hair Coverage From Baseline
Participant satisfaction question was used to assess overall satisfaction with hair coverage, with responses ranging from 1 to 5, as follows: 1 (very dissatisfied), 2 (dissatisfied), 3 (somewhat satisfied), 4 (mostly satisfied), 5 (very satisfied). Higher scores indicate better satisfaction with hair coverage. The percentage of participants with change from Baseline to Weeks 8, 12 and 24 satisfaction level was reported as categories: satisfied to satisfied; satisfied to dissatisfied; dissatisfied to satisfied and dissatisfied to dissatisfied. Data is reported only for participants with change from Baseline in satisfaction level.
Time frame: Baseline, Weeks 8, 12 and 24
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event.
Time frame: From first dose up to 28 weeks
Participants were enrolled at 12 study centers in Canada and the United States from 24 May 2019 to 10 April 2020.
| Milestone | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| Started | 34 | 32 |
| Safety population | 34 | 32 |
| Mitt population | 34 | 32 |
| Completed | 33 | 30 |
| Not completed | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal of informed consent due to an adverse event | 1 | 0 |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).
| percent change | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 | 58.44 ± 34.747 | 51.96 ± 37.887 |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Percentage of participants achieving at least a 50%, 75%, 90% relative reduction in SALT score from baseline at Weeks 4, 8, 12, 16, 20, and 24 are reported.
| percentage of participants | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| 90% Reduction: Week 4 | 0.0 | 0.0 |
| 90% Reduction: Week 8 | 0.0 | 0.0 |
| 90% Reduction: Week 12 | 8.8 | 6.3 |
| 90% Reduction: Week 16 | 20.6 | 12.5 |
| 90% Reduction: Week 20 | 32.4 | 21.9 |
| 90% Reduction: Week 24 | 32.4 | 31.3 |
| 75% Reduction: Week 4 | 0.0 | 0.0 |
| 75% Reduction: Week 8 | 0.0 | 0.0 |
| 75% Reduction: Week 12 | 14.7 | 18.8 |
| 75% Reduction: Week 16 | 23.5 | 25.0 |
| 75% Reduction: Week 20 | 35.3 | 31.3 |
| 75% Reduction: Week 24 | 38.2 | 34.4 |
| 50% Reduction: Week 4 | 0.0 | 0.0 |
| 50% Reduction: Week 8 | 8.8 | 0.0 |
| 50% Reduction: Week 12 | 32.4 | 31.3 |
| 50% Reduction: Week 16 | 44.1 | 40.6 |
| 50% Reduction: Week 20 | 52.9 | 43.8 |
| 50% Reduction: Week 24 | 61.8 | 53.1 |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Absolute change equals the difference in SALT measurements (baseline SALT score - follow-up SALT score).
| score on a scale | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| Change from Baseline at Week 4 | 1.95 ± 4.247 | 3.02 ± 5.211 |
| Change from Baseline at Week 8 | 11.68 ± 17.674 | 13.61 ± 15.795 |
| Change from Baseline at Week 12 | 26.07 ± 28.086 | 25.33 ± 27.874 |
| Change from Baseline at Week 16 | 38.83 ± 30.699 | 31.32 ± 28.637 |
| Change from Baseline at Week 20 | 45.44 ± 32.169 | 37.78 ± 31.021 |
| Change from Baseline at Week 24 | 48.63 ± 31.733 | 42.82 ± 31.470 |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).
| percent change | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| Change from Baseline at Week 4 | 3.12 ± 7.474 | 3.95 ± 7.126 |
| Change from Baseline at Week 8 | 14.57 ± 19.800 | 17.24 ± 19.034 |
| Change from Baseline at Week 12 | 32.10 ± 30.960 | 31.90 ± 33.820 |
| Change from Baseline at Week 16 | 47.20 ± 34.663 | 39.08 ± 35.750 |
| Change from Baseline at Week 20 | 54.58 ± 35.582 | 46.24 ± 37.891 |
Participant satisfaction question was used to assess overall satisfaction with hair coverage, with responses ranging from 1 to 5, as follows: 1 (very dissatisfied), 2 (dissatisfied), 3 (somewhat satisfied), 4 (mostly satisfied), 5 (very satisfied). Higher scores indicate better satisfaction with hair coverage. The percentage of participants with change from Baseline to Weeks 8, 12 and 24 satisfaction level was reported as categories: satisfied to satisfied; satisfied to dissatisfied; dissatisfied to satisfied and dissatisfied to dissatisfied. Data is reported only for participants with change from Baseline in satisfaction level.
| percentage of participants | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| Week 8: Satisfied to Satisfied | 3.6 | 0 |
| Week 8: Satisfied to Dissatisfied | 0 | 0 |
| Week 8: Dissatisfied to Satisfied | 39.3 | 44.8 |
| Week 8: Dissatisfied to Dissatisfied | 57.1 | 55.2 |
| Week 12: Satisfied to Satisfied | 6.5 | 0 |
| Week 12: Satisfied to Dissatisfied | 0 | 0 |
| Week 12: Dissatisfied to Satisfied | 35.5 | 67.7 |
| Week 12: Dissatisfied to Dissatisfied | 58.1 | 32.3 |
| Week 24: Satisfied to Satisfied | 6.3 | 0 |
| Week 24: Satisfied to Dissatisfied | 0 | 0 |
| Week 24: Dissatisfied to Satisfied | 68.8 | 70.0 |
| Week 24: Dissatisfied to Dissatisfied | 25.0 | 30.0 |
An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event.
| Participants | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) | 28 | 24 |
Collected over From first dose up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CTP-543 12 mg BID | 0/34 (0%) | 0/34 (0%) | 28/34 (82.4%) |
| CTP-543 24 mg QD | 0/32 (0%) | 1/32 (3.1%) | 24/32 (75%) |
| Event | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| SyncopeNervous system disorders | 0/34 | 1/32 |
| Event | CTP-543 12 mg BID | CTP-543 24 mg QD |
|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 11/34 | 4/32 |
| Upper respiratory tract infectionGeneral disorders | 4/34 | 6/32 |
| HeadacheNervous system disorders | 3/34 | 6/32 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/34 | 4/32 |
| NasopharyngitisGeneral disorders | 4/34 | 3/32 |
| Lipase increasedInvestigations | 4/34 | 1/32 |
| AcneSkin and subcutaneous tissue disorders | 4/34 | 2/32 |
| FolliculitisGeneral disorders | 0/34 | 3/32 |
| Urinary tract infectionGeneral disorders | 1/34 | 3/32 |
| Weight increasedInvestigations | 3/34 | 3/32 |
Safety population included all participants who received at least one dose of study drug. Participants were summarized according to study drug regimen received.
| Age, Continuous(years) | CTP-543 12 mg BID | CTP-543 24 mg QD | Total |
|---|---|---|---|
| Mean | 38.8 ± 11.89 | 40.4 ± 14.20 | 39.6 ± 12.99 |
| Sex: Female, Male(Participants) | CTP-543 12 mg BID | CTP-543 24 mg QD | Total |
|---|---|---|---|
| Female | 21 | 23 | 44 |
| Male | 13 | 9 | 22 |
| Ethnicity (NIH/OMB)(Participants) | CTP-543 12 mg BID | CTP-543 24 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 34 | 29 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CTP-543 12 mg BID | CTP-543 24 mg QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 4 | 4 | 8 |
| White | 25 | 23 | 48 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Severity of Alopecia Tool (SALT) Score(score on a scale) | CTP-543 12 mg BID | CTP-543 24 mg QD | Total |
|---|---|---|---|
| Mean | 85.77 ± 19.473 | 87.76 ± 17.280 | 86.73 ± 18.328 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Apr 2020, 10 months.
Results were first posted in Apr 2023, 2 years 11 months after primary completion. A results delay was requested in Mar 2021.
Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deuruxolitinib